UNSPSC 51281505: Protionamide

This classification denotes an antitubercular agent with the molecular formula C9H12N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76YOO33643, chemically known as 4-pyridinecarbothioamide, 2-propyl- (9ci) but generally known as protionamide, which bears US NIH Compound Identifier 666418. European Medicines Agency schedules Protionamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10141MIG.

UNSPSC 51281505 Protionamide is a Commodity code that covers pharmaceutical products, though recent state and local solicitations under this code show little direct activity focused on protionamide itself. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract to Chartwell Rx LLC in August 2026 for antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) through the MMCAP Infuse consortium, totaling $2,999,999.11 over 12 months plus two optional renewal years. Separately, Seminole County, Florida released an IFB in June 2026 for Naloxone and Safe Drug Deactivation Systems for community health initiatives. State and local buyers procuring under this code span state health departments, county government, and special-purpose health authorities; Illinois Department of Public Health and Seminole County are recent issuing bodies. These jurisdictions source pharmaceutical products through both direct award and cooperative purchasing arrangements, with contracts typically structured around fixed pricing, annual terms with renewal options, and quarterly or as-needed delivery schedules.

The code shows recent activity in Illinois and Florida. The Illinois award covers a 12-month base contract with renewal options, while the Seminole County solicitation (IFB 60459723LAS, due July 26, 2023, though posted June 30, 2026) called for 1,900 units of Naloxone and 800 deactivation systems annually with quarterly deliveries. Neither recent opportunity directly targets protionamide; the pharmaceutical categories under this code appear to span a broader range of drugs and medical products sourced by county and state health systems. Vendors entering this space should expect cooperative purchasing mechanisms like MMCAP Infuse, fixed-fee pricing models, multi-year contract structures, compliance requirements including E-Verify and drug-free workplace certification, and delivery-inclusive proposals. Activity is sporadic and geographically scattered rather than concentrated in a single jurisdiction or region.